Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1143 | A-1210477 | Mcl-1 | Misc | 16.3987 | 0.6719 | 0.0640 | 0.0008 | 1.0821 | 44.847 | 0.81227 |
HCC1143 | Olaparib | PARP | Misc | 8.8262 | 0.4562 | 0.0925 | 0.0158 | 0.7545 | 37.8573 | 0.98047 |
HCC1143 | Bleomycin | Radiation | Misc | 0.04818 | -0.2085 | 0.6578 | 0.1955 | 1.0629 | 0.066427 | 0.9974 |
HCC1143 | Ipatasertib | AKT | PI3K/mTOR | 80.6794 | 0.7509 | 0.0662 | -0.0023 | 0.4354 | 999.9134 | 0.83579 |
HCC1143 | Alpelisib | PI3Ka | PI3K/mTOR | 9.8836 | 0.4797 | 0.1743 | 0.0189 | 0.3582 | 212.3193 | 0.93833 |
HCC1143 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.21535 | -0.0942 | 0.4758 | 0.0890 | 0.3239 | 6.4012 | 0.99147 |
HCC1143 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9185 | 0.0347 | 0.0040 | 4.9981 | 0.020639 | 0.76284 |
HCC1143 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.044657 | -0.1535 | 0.3642 | 0.0851 | 1.0643 | 0.061723 | 0.99242 |
HCC1143 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.5574 | 0.3426 | 0.0295 | 0.1006 | 0.071342 | 0.79962 |
HCC1143 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.04046 | 0.0314 | 0.4743 | 0.0660 | 0.7035 | 0.039906 | 0.9903 |
HCC1143 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.7394 | 0.0639 | 0.0042 | 0.6101 | 17.8472 | 0.96209 |
HCC1143 | Buparlisib | pan PI3K | PI3K/mTOR | 0.7249 | -0.4360 | 0.3915 | 0.1265 | 1.3299 | 1.2866 | 0.98685 |
HCC1143 | Pictilisib | pan PI3K | PI3K/mTOR | 0.97831 | -0.1291 | 0.3201 | 0.0583 | 0.5213 | 8.0489 | 0.97859 |
HCC1143 | Ceritinib | ALK | RTK | 1.4479 | -0.4219 | 0.2848 | 0.0621 | 1.0347 | 4.1868 | 0.99172 |
HCC1143 | Neratinib | EGFR/HER2 | RTK | 0.67229 | 0.0791 | 0.2379 | 0.0489 | 0.5527 | 4.9078 | 0.98415 |
HCC1143 | Tivantinib | MET | RTK | 0.27789 | -0.3122 | 0.4977 | 0.1369 | 1.9433 | 0.35725 | 0.99341 |
HCC1143 | Cediranib | VEGFR/cKIT | RTK | 3.7314 | 0.0093 | 0.1653 | 0.0292 | 1.0590 | 10.5294 | 0.98332 |
HCC1143 | Cabozantinib | VEGFR2/MET | RTK | 10.6105 | 0.5122 | 0.1025 | 0.0156 | 0.9383 | 34.2157 | 0.84631 |
PDXHCI002 | Abemaciclib | CDK4/6 | Cell cycle | 0.047944 | -0.6767 | 0.7662 | 0.1664 | 0.6873 | 0.18848 | 0.98885 |
PDXHCI002 | Palbociclib | CDK4/6 | Cell cycle | 0.12955 | 0.2766 | 0.2793 | -0.0122 | 1.1851 | 0.053617 | 0.97783 |
PDXHCI002 | AZD7762 | CHK1/2 | Cell cycle | 0.067995 | -0.5815 | 0.7079 | 0.2347 | 0.8162 | 0.19222 | 0.98921 |
PDXHCI002 | Volasertib | PLK | Cell cycle | 0.0037003 | -0.5892 | 0.8480 | 0.3925 | 4.6276 | 0.0042869 | 0.99531 |
PDXHCI002 | Dinaciclib | pan CDK | Cell cycle | 0.012194 | -0.3607 | 0.6030 | 0.2029 | 4.6252 | 0.01372 | 0.99728 |
PDXHCI002 | Cisplatin | Chemo | Chemotherapy | 1.7306 | -0.0985 | 0.2044 | -0.0257 | 1.2874 | 2.4053 | 0.98631 |
PDXHCI002 | Doxorubicin | Chemo | Chemotherapy | 0.0040539 | -0.6545 | 0.9685 | 0.2951 | 0.9297 | 0.0087544 | 0.98094 |